Citi analyst Geoff Meacham has maintained their bullish stance on BNTX stock, giving a Buy rating today.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Geoff Meacham’s rating is based on BioNTech’s strategic acquisition of CureVac, which enhances its transition into an oncology-focused company utilizing mRNA technologies. This acquisition brings in CureVac’s neoantigen cancer vaccines, complementing BioNTech’s existing programs and expanding its portfolio, particularly with the promising CVGBM vaccine for glioblastoma.
Additionally, the acquisition provides BioNTech with a diversified pipeline, reducing reliance on respiratory vaccines and mitigating seasonal and policy-related risks. The transaction terms, including the share exchange, imply a significant equity value for CureVac, and the expected share price return of 32.8% further supports the Buy rating.
Meacham covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Pfizer, and Merck & Company. According to TipRanks, Meacham has an average return of 2.1% and a 52.82% success rate on recommended stocks.
In another report released today, Deutsche Bank also maintained a Buy rating on the stock with a $140.00 price target.
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue